Isorhamnetin Cancer Research Results

ISO, IH, Isorhamnetin: Click to Expand ⟱
Features:
Scientific Papers found: Click to Expand⟱
9247- ISO, IH,  capec,    Isorhamnetin augments the anti-tumor effect of capecitabine through the negative regulation of NF-κB signaling cascade in gastric cancer
- vitro+vivo, GC, NA
tumCV↓, Synergy↑, NF-kB↓, TumCG↑,
9255- ISO, IH,    Isorhamnetin Modulates Drug-Resistance-Related Biomarkers in Colon Cancer Cells
- in-vitro, Colon, SW48 - in-vitro, CRC, HT-29
CYP1A1↓, CYP1B1↓, MRP1/ABCC1↓, MRP5↓, P-gp/ABCB1↓, GSTs↓, tumCV↓, TumCP↓,
9254- ISO, IH,    Isorhamnetin: what is the in vitro evidence for its antitumor potential and beyond?
- Review, Var, NA
MMP2↓, MMP9↓, MAPK↓, STAT3↓, Akt↓, mTOR↓, MEK↓, ERK↓, TumCP↓, TumCM/A↓, LDH↓, EMT↓, Casp3↑, Cyt‑c↑, BAX↑, cl‑Casp3↑, cl‑PARP↑, TumCCA?, AMPK↑, ROS↑, COX2/PTGS2↓, *cardioP↑, *hepatoP↑, *neuroP↑, *RenoP↑, *AntiViral↑, *antiCG↑, *AntiAg↑, *AntiThr↑,
9253- ISO, IH,    Progress in the antitumor molecular mechanisms of Isorhamnetin
- Review, Var, NA
*antiOx↑, *Inflam↓, *AntiTum↑, TumCP↓, Apoptosis↑, TumCP↓, TumCI↓, TumCMig↓, ChemoSen↑, PI3K↓, Akt↓, TumCCA↑, MAPK↓, TumCG↓, CDK2↑, PPARγ↑, PTEN↓, CAIX/CA9↓, Casp8↑, Casp9↑, Casp3↑, ROS↑, ER Stress↑, UPR↑, BAX↑, Cyt‑c↑, cl‑PARP↑, Bcl-2↓, MMP↓, N-cadherin↓, Vim↓, Snail↓, E-cadherin↑, EMT↓, MMP2↓, MMP9↓,
9252- ISO, IH,    Isorhamnetin: Reviewing Recent Developments in Anticancer Mechanisms and Nanoformulation-Driven Delivery
- Review, Var, NA
TumCP↓, Apoptosis↑, Casp↑, mtDam↑, MMPs↓, VEGF↓, EMT↓, *antiOx↓, *Inflam↓, *ROS↓, MDR1↓, PI3K↓, Akt↓, MAPK↓, NF-kB↓, Ingr↝, TumCCA↑, CycB/CCNB1↓, CDK1↓, P21↑, ROS↑, AMPK↑, *Ferroptosis↓, *NRF2↑, *HO-1↑, *IronCh↑, *lipid-P↓, *GSH↑, *ACSL4↓, *COX2/PTGS2↓, VEGF↓, angioG↓, E-cadherin↑, N-cadherin↓, uPA↓, *NK cell↑, radioP↑, Imm↑, Neut↑, Eos↑,
9251- ISO, IH,    Advances in Isorhamnetin Treatment of Malignant Tumors: Mechanisms and Applications
- Review, Var, NA
BioAv↑, RenoP↑, chemoP↑, *Ingr↝, *cardioP↑, *antiOx↑, *Stroke↓, *AntiThr↑, *neuroP↑, *cognitive↑, *memory↑, *Inflam↓, *Bacteria↓, *AntiViral↑, *NRF2↑, *TNF-α↓, *NO↓, *IL1β↓, *ROS↓, TumCCA↑, TumCP↓, PI3K↓, Akt↓, MET↑, MMPs↓, MMP2↓, MMP9↓, mTOR↓, PPARγ↓, PTEN↓, CAIX/CA9↓, Cyt‑c↑, ROS↑, cl‑Casp3↑, cl‑PARP↑, BAX↑, Bcl-2↓, ChemoSen↑, chemoP↑, RenoP↑, BioAv↓,
9250- ISO, IH,    Absorption, excretion and metabolite profiling of methyl-, glucuronyl-, glucosyl- and sulpho-conjugates of quercetin in human plasma and urine after ingestion of onions
- Study, Nor, NA
*BioAv↑, *Half-Life↝,
9249- ISO, IH,    Isorhamnetin alleviates cisplatin-induced acute kidney injury via enhancing fatty acid oxidation
- in-vivo, Nor, NA
*chemoP↑, *Apoptosis↓, *Inflam↓, *RenoP↑, *lipidLev↓, *PGC-1α↑, *PPARα↑, *CPT1A↑, *FAO↑,
9248- ISO, IH,  Cisplatin,  carbop,    Isorhamnetin flavonoid synergistically enhances the anticancer activity and apoptosis induction by cis-platin and carboplatin in non-small cell lung carcinoma (NSCLC)
- in-vitro, Lung, A549
ChemoSen↑, Apoptosis↑, TumCCA↑, MMP↓, Casp3↑, Casp9↑, PARP↑, TumCMig↓, Dose↝,
9239- ISO, IH,    Isorhamnetin suppresses colon cancer cell growth through the PI3K‑Akt‑mTOR pathway
- in-vitro, CRC, HT-29 - in-vitro, CRC, HCT116 - in-vitro, Colon, SW480
TumCP↓, TumCCA↑, PI3K↓, Akt↓, mTOR↓, CycB/CCNB1↑,
9246- ISO, IH,    Isorhamnetin inhibits migration and promotes apoptosis via modulation of oxidative stress, mitochondrial dysfunction, and the TIGIT/CD155 axis in 4T1 breast cancer cells
- in-vitro, BC, 4T1
TumCP↓, TumCMig↓, Tumccf↓, ROS↑, MMP↓, CD155↓, TIGIT↓,
9245- ISO, IH,    Autophagy inhibition enhances isorhamnetin‑induced mitochondria‑dependent apoptosis in non‑small cell lung cancer cells
- in-vitro, Lung, A549
TumCP↓, Tumccf↓, Apoptosis↑, MMP↓, Cyt‑c↑, LC3II↑, NA↑,
9244- ISO, IH,    Isorhamnetin inhibits bladder cancer progression by mediating glycolysis through targeting the SRC/PI3K/Akt axis
- in-vitro, Bladder, 5637
TumCP↓, TumCMig↓, TumCI↓, TumCA↓, Glycolysis↓, TumCCA↑, Apoptosis↑, p‑Src↓, PI3K↓, Akt↓, mTOR↓, HK2↓, GLUT1↓, PFKFB3↓, ECAR↓, OCR↓, GlucoseCon↓, lactateProd↓,
9243- ISO, IH,    Isorhamnetin Inhibits Reactive Oxygen Species-Dependent Hypoxia Inducible Factor (HIF)-1α Accumulation
- in-vitro, CRC, HCT116 - in-vitro, CRC, HT-29
Hif1a↓, GLUT1↓, LDHA↓, CAIX/CA9↓, PDK1 / PDPK1↓, ROS↓,
9242- ISO, IH,    Isorhamnetin Induces Melanoma Cell Apoptosis via the PI3K/Akt and NF- κ B Pathways
- vitro+vivo, Melanoma, B16-BL6
TumCP↓, TumCMig↓, Apoptosis↑, p‑Akt↓, NF-kB↓, PFKFB4?, BAX↑, Casp3↑, Bcl-2↓,
9241- ISO, IH,    Isorhamnetin inhibited the proliferation and metastasis of androgen-independent prostate cancer cells by targeting the mitochondrion-dependent intrinsic apoptotic and PI3K/Akt/mTOR pathway
- in-vitro, Pca, DU145 - in-vitro, Pca, PC3
TumCG↓, LDH↓, selectivity↑, TumCMig?, TumCI?, MET↑, MMP2↓, MMP9↓, PI3K↓, Akt↓, mTOR↓, Bcl-2↓, BAX↑, Cyt‑c↑, cl‑PARP↑, E-cadherin↑, Vim↓, N-cadherin↓,
9240- ISO, IH,    Isorhamnetin inhibits cell proliferation and induces apoptosis in breast cancer via Akt and mitogen‑activated protein kinase kinase signaling pathways
- in-vitro, BC, NA
TumCP↓, Apoptosis↑, Akt↓, mTOR↓,

Showing Research Papers: 1 to 17 of 17

* indicates research on normal cells as opposed to diseased cells
Total Research Paper Matches: 17

Pathway results for Effect on Cancer / Diseased Cells:


NA, unassigned(tgid=0) ⓘ

NA↑, 1,  

Redox & Oxidative Stress(tgid=1) ⓘ

GSTs↓, 1,   ROS↓, 1,   ROS↑, 5,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

mtDam↑, 1,   OCR↓, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

AMPK↑, 2,   CAIX/CA9↓, 3,   ECAR↓, 1,   GlucoseCon↓, 1,   Glycolysis↓, 1,   HK2↓, 1,   lactateProd↓, 1,   LDHA↓, 1,   PDK1 / PDPK1↓, 1,   PFKFB3↓, 1,   PFKFB4?, 1,   TumCM/A↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↑, 7,   BAX↑, 5,   Bcl-2↓, 4,   Casp↑, 1,   Casp3↑, 4,   cl‑Casp3↑, 2,   Casp8↑, 1,   Casp9↑, 2,   Cyt‑c↑, 5,  

Kinase & Signal Transduction(tgid=6) ⓘ

Akt↓, 8,   p‑Akt↓, 1,   ERK↓, 1,   MAPK↓, 3,   MEK↓, 1,   mTOR↓, 6,   PI3K↓, 6,   PTEN↓, 2,   p‑Src↓, 1,   STAT3↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

tumCV↓, 2,  

Protein Folding & ER Stress(tgid=8) ⓘ

ER Stress↑, 1,   UPR↑, 1,  

Autophagy & Lysosomes(tgid=9) ⓘ

LC3II↑, 1,  

DNA Damage & Repair(tgid=10) ⓘ

PARP↑, 1,   cl‑PARP↑, 4,  

Cell Cycle & Senescence(tgid=11) ⓘ

CDK1↓, 1,   CDK2↑, 1,   CycB/CCNB1↓, 1,   CycB/CCNB1↑, 1,   P21↑, 1,   TumCCA?, 1,   TumCCA↑, 6,  

Proliferation, Differentiation & Cell State(tgid=12) ⓘ

TumCG↓, 2,   TumCG↑, 1,   TumCP↓, 12,  

Migration(tgid=13) ⓘ

E-cadherin↑, 3,   EMT↓, 3,   MET↑, 2,   MMP2↓, 4,   MMP9↓, 4,   MMPs↓, 2,   N-cadherin↓, 3,   Snail↓, 1,   TumCA↓, 1,   TumCI?, 1,   TumCI↓, 2,   TumCMig?, 1,   TumCMig↓, 5,   uPA↓, 1,   Vim↓, 2,  

Angiogenesis & Vasculature(tgid=14) ⓘ

angioG↓, 1,   Hif1a↓, 1,   VEGF↓, 2,  

Barriers & Transport(tgid=15) ⓘ

GLUT1↓, 2,   MMP↓, 4,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

CD155↓, 1,   COX2/PTGS2↓, 1,   Eos↑, 1,   Imm↑, 1,   Neut↑, 1,   NF-kB↓, 3,   TIGIT↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARγ↓, 1,   PPARγ↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↓, 1,   BioAv↑, 1,   ChemoSen↑, 3,   CYP1A1↓, 1,   CYP1B1↓, 1,   Dose↝, 1,   MDR1↓, 1,   MRP1/ABCC1↓, 1,   MRP5↓, 1,   P-gp/ABCB1↓, 1,   selectivity↑, 1,   Synergy↑, 1,  

Clinical Biomarkers(tgid=22) ⓘ

LDH↓, 2,   Tumccf↓, 2,  

Functional Outcomes(tgid=23) ⓘ

chemoP↑, 2,   radioP↑, 1,   RenoP↑, 2,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 100

Pathway results for Effect on Normal Cells:


Redox & Oxidative Stress(tgid=1) ⓘ

antiOx↓, 1,   antiOx↑, 2,   GSH↑, 1,   HO-1↑, 1,   lipid-P↓, 1,   NRF2↑, 2,   ROS↓, 2,  

Metal & Cofactor Biology(tgid=2) ⓘ

IronCh↑, 1,  

Mitochondria & Bioenergetics(tgid=3) ⓘ

PGC-1α↑, 1,  

Core Metabolism/Glycolysis(tgid=4) ⓘ

ACSL4↓, 1,   CPT1A↑, 1,   FAO↑, 1,   lipidLev↓, 1,  

Cell Death(tgid=5) ⓘ

Apoptosis↓, 1,   Ferroptosis↓, 1,  

Transcription & Epigenetics(tgid=7) ⓘ

AntiThr↑, 2,  

Migration(tgid=13) ⓘ

AntiAg↑, 1,  

Angiogenesis & Vasculature(tgid=14) ⓘ

NO↓, 1,  

Immune & Inflammatory Signaling(tgid=16) ⓘ

COX2/PTGS2↓, 1,   IL1β↓, 1,   Inflam↓, 4,   NK cell↑, 1,   TNF-α↓, 1,  

Hormonal & Nuclear Receptors(tgid=20) ⓘ

PPARα↑, 1,  

Drug Metabolism & Resistance(tgid=21) ⓘ

BioAv↑, 1,   Half-Life↝, 1,  

Functional Outcomes(tgid=23) ⓘ

antiCG↑, 1,   AntiTum↑, 1,   cardioP↑, 2,   chemoP↑, 1,   cognitive↑, 1,   hepatoP↑, 1,   memory↑, 1,   neuroP↑, 2,   RenoP↑, 2,   Stroke↓, 1,  

Infection & Microbiome(tgid=24) ⓘ

AntiViral↑, 2,   Bacteria↓, 1,  

Ingredients & Constituents(tgid=25) ⓘ

Ingr↝, 1,  
Total Targets: 39

Query results interpretion may depend on "conditions" listed in the research papers.
Such Conditions may include : 
  -low or high Dose
  -format for product, such as nano of lipid formations
  -different cell line effects
  -synergies with other products 
  -if effect was for normal or cancerous cells
Filter Conditions: Pro/AntiFlg:%  IllCat:%  CanType:%  Cells:%  prod#:519  Target#:%  State#:%  Dir#:%
wNotes=0 sortOrder:rid,rpid

 

Home Page